BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology. 2009;50:1773-1782. [PMID: 19937696 DOI: 10.1002/hep.23226] [Cited by in Crossref: 246] [Cited by in F6Publishing: 229] [Article Influence: 20.5] [Reference Citation Analysis]
Number Citing Articles
1 Velazquez-Salinas L, Verdugo-Rodriguez A, Rodriguez LL, Borca MV. The Role of Interleukin 6 During Viral Infections. Front Microbiol. 2019;10:1057. [PMID: 31134045 DOI: 10.3389/fmicb.2019.01057] [Cited by in Crossref: 147] [Cited by in F6Publishing: 105] [Article Influence: 73.5] [Reference Citation Analysis]
2 Lauterbach-Rivière L, Bergez M, Mönch S, Qu B, Riess M, Vondran FWR, Liese J, Hornung V, Urban S, König R. Hepatitis B Virus DNA is a Substrate for the cGAS/STING Pathway but is not Sensed in Infected Hepatocytes. Viruses 2020;12:E592. [PMID: 32485908 DOI: 10.3390/v12060592] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 15.0] [Reference Citation Analysis]
3 Lan T, Chang L, Wu L, Yuan YF. IL-6 Plays a Crucial Role in HBV Infection. J Clin Transl Hepatol 2015;3:271-6. [PMID: 26807383 DOI: 10.14218/JCTH.2015.00024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
4 Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel M, Autran B, Cosset F, Strick-marchand H, Trépo C, Kao J, Carrat F, Lacombe K, Schinazi RF, Barré-sinoussi F, Delfraissy J, Zoulim F. Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26. [DOI: 10.1136/gutjnl-2014-308943] [Cited by in Crossref: 186] [Cited by in F6Publishing: 168] [Article Influence: 31.0] [Reference Citation Analysis]
5 Naseem S, Hussain T, Manzoor S. Interleukin-6: A promising cytokine to support liver regeneration and adaptive immunity in liver pathologies. Cytokine Growth Factor Rev 2018;39:36-45. [PMID: 29361380 DOI: 10.1016/j.cytogfr.2018.01.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
6 Wang Q, Chen X, Feng J, Cao Y, Song Y, Wang H, Zhu C, Liu S, Zhu Y. Soluble interleukin-6 receptor-mediated innate immune response to DNA and RNA viruses. J Virol 2013;87:11244-54. [PMID: 23946454 DOI: 10.1128/JVI.01248-13] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
7 Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B. Nat Rev Gastroenterol Hepatol. 2019;16:662-675. [PMID: 31548710 DOI: 10.1038/s41575-019-0196-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 16.5] [Reference Citation Analysis]
8 Carroll MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther. 2011;11:533-544. [PMID: 21269234 DOI: 10.1517/14712598.2011.554810] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
9 Ma Y, Yang M, He Z, Wei Q, Li J. The Biological Function of Kupffer Cells in Liver Disease. In: Ghosh A, editor. Biology of Myelomonocytic Cells. InTech; 2017. [DOI: 10.5772/67673] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Cai Y, Yin W. The Multiple Functions of B Cells in Chronic HBV Infection. Front Immunol 2020;11:582292. [PMID: 33381113 DOI: 10.3389/fimmu.2020.582292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 2012;8:348-57. [DOI: 10.1038/nrrheum.2012.63] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
12 Xu C, Guo H, Pan XB, Mao R, Yu W, Xu X, Wei L, Chang J, Block TM, Guo JT. Interferons accelerate decay of replication-competent nucleocapsids of hepatitis B virus. J Virol. 2010;84:9332-9340. [PMID: 20610715 DOI: 10.1128/jvi.00918-10] [Cited by in Crossref: 91] [Cited by in F6Publishing: 58] [Article Influence: 8.3] [Reference Citation Analysis]
13 Chen J, Xu W, Chen Y, Xie X, Zhang Y, Ma C, Yang Q, Han Y, Zhu C, Xiong Y, Wu K, Liu F, Liu Y, Wu J. Matrix Metalloproteinase 9 Facilitates Hepatitis B Virus Replication through Binding with Type I Interferon (IFN) Receptor 1 To Repress IFN/JAK/STAT Signaling. J Virol 2017;91:e01824-16. [PMID: 28122987 DOI: 10.1128/JVI.01824-16] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
14 Busca A, Kumar A. Innate immune responses in hepatitis B virus (HBV) infection. Virol J. 2014;11:22. [PMID: 24507433 DOI: 10.1186/1743-422x-11-22] [Cited by in Crossref: 79] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
15 Yang P, Markowitz GJ, Wang XF. The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma. Natl Sci Rev 2014;1:396-412. [PMID: 25741453 DOI: 10.1093/nsr/nwu038] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
16 Liu HY, Zhang XY. Innate immune recognition of hepatitis B virus. World J Hepatol 2015;7:2319-22. [PMID: 26413220 DOI: 10.4254/wjh.v7.i21.2319] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
17 Wu W, Wu D, Yan W, Wang Y, You J, Wan X, Xi D, Luo X, Han M, Ning Q. Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p. J Infect Dis 2021;223:686-98. [PMID: 32663850 DOI: 10.1093/infdis/jiaa399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
18 Janovec V, Hodek J, Clarova K, Hofman T, Dostalik P, Fronek J, Chlupac J, Chaperot L, Durand S, Baumert TF, Pichova I, Lubyova B, Hirsch I, Weber J. Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes. Sci Rep 2020;10:12767. [PMID: 32728070 DOI: 10.1038/s41598-020-69614-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Gehring AJ. New treatments to reach functional cure: Rationale and challenges for emerging immune-based therapies. Best Practice & Research Clinical Gastroenterology 2017;31:337-45. [DOI: 10.1016/j.bpg.2017.05.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
20 Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One. 2011;6:e15324. [PMID: 21246041 DOI: 10.1371/journal.pone.0015324.] [Reference Citation Analysis]
21 Pei R, Qin B, Zhang X, Zhu W, Kemper T, Ma Z, Trippler M, Schlaak J, Chen X, Lu M. Interferon-induced proteins with tetratricopeptide repeats 1 and 2 are cellular factors that limit hepatitis B virus replication. J Innate Immun. 2014;6:182-191. [PMID: 23867918 DOI: 10.1159/000353220] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
22 Ko C, Michler T, Protzer U. Novel viral and host targets to cure hepatitis B. Current Opinion in Virology 2017;24:38-45. [DOI: 10.1016/j.coviro.2017.03.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
23 Hou X, Hao X, Zheng M, Xu C, Wang J, Zhou R, Tian Z. CD205-TLR9-IL-12 axis contributes to CpG-induced oversensitive liver injury in HBsAg transgenic mice by promoting the interaction of NKT cells with Kupffer cells. Cell Mol Immunol. 2017;14:675-684. [PMID: 27041637 DOI: 10.1038/cmi.2015.111] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
24 van de Garde MD, Movita D, van der Heide M, Herschke F, De Jonghe S, Gama L, Boonstra A, Vanwolleghem T. Liver Monocytes and Kupffer Cells Remain Transcriptionally Distinct during Chronic Viral Infection. PLoS One 2016;11:e0166094. [PMID: 27812182 DOI: 10.1371/journal.pone.0166094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
25 He J, Hao R, Liu D, Liu X, Wu S, Guo S, Wang Y, Tien P, Guo D. Inhibition of hepatitis B virus replication by activation of the cGAS-STING pathway. Journal of General Virology 2016;97:3368-78. [DOI: 10.1099/jgv.0.000647] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
26 Kim DH, Kang HS, Kim KH. Roles of hepatocyte nuclear factors in hepatitis B virus infection. World J Gastroenterol 2016;22:7017-29. [PMID: 27610013 DOI: 10.3748/wjg.v22.i31.7017] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
27 Lang J, Neumann-haefelin C, Thimme R. Immunological cure of HBV infection. Hepatol Int 2019;13:113-24. [DOI: 10.1007/s12072-018-9912-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
28 Banerjee I, Fisher PB, Sarkar D. Astrocyte elevated gene-1 (AEG-1): A key driver of hepatocellular carcinoma (HCC). Adv Cancer Res 2021;152:329-81. [PMID: 34353442 DOI: 10.1016/bs.acr.2021.05.003] [Reference Citation Analysis]
29 Rehermann B, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. Gastroenterology 2019;156:369-83. [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 16.7] [Reference Citation Analysis]
30 Michler T, Kosinska AD, Festag J, Bunse T, Su J, Ringelhan M, Imhof H, Grimm D, Steiger K, Mogler C, Heikenwalder M, Michel ML, Guzman CA, Milstein S, Sepp-Lorenzino L, Knolle P, Protzer U. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice. Gastroenterology 2020;158:1762-1775.e9. [PMID: 32001321 DOI: 10.1053/j.gastro.2020.01.032] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 20.0] [Reference Citation Analysis]
31 Ma Z, Zhang E, Yang D, Lu M. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses. Cell Mol Immunol. 2015;12:273-282. [PMID: 25418467 DOI: 10.1038/cmi.2014.112] [Cited by in Crossref: 64] [Cited by in F6Publishing: 54] [Article Influence: 9.1] [Reference Citation Analysis]
32 Yi Z, Chen J, Kozlowski M, Yuan Z. Innate detection of hepatitis B and C virus and viral inhibition of the response. Cell Microbiol 2015;17:1295-303. [PMID: 26243406 DOI: 10.1111/cmi.12489] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
33 Kim DH, Park ES, Lee AR, Park S, Park YK, Ahn SH, Kang HS, Won JH, Ha YN, Jae B, Kim DS, Chung WC, Song MJ, Kim KH, Park SH, Kim SH, Kim KH. Intracellular interleukin-32γ mediates antiviral activity of cytokines against hepatitis B virus. Nat Commun 2018;9:3284. [PMID: 30115930 DOI: 10.1038/s41467-018-05782-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
34 Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T. Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem. 2013;288:31715-31727. [PMID: 24025329 DOI: 10.1074/jbc.m113.501122] [Cited by in Crossref: 99] [Cited by in F6Publishing: 48] [Article Influence: 12.4] [Reference Citation Analysis]
35 Durantel D, Zoulim F. Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option? J Hepatol 2012;57:486-9. [PMID: 22728561 DOI: 10.1016/j.jhep.2012.06.019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
36 Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, Hervieu V, Berthillon P, Berby F, Bordes I, Durantel D, Levrero M, Lampertico P, Zoulim F. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. Journal of Hepatology 2017;66:897-909. [DOI: 10.1016/j.jhep.2016.12.024] [Cited by in Crossref: 76] [Cited by in F6Publishing: 69] [Article Influence: 19.0] [Reference Citation Analysis]
37 Li M, Yang J, Zhao Y, Song Y, Yin S, Guo J, Zhang H, Wang K, Wei L, Li S, Xu W. MCPIP1 inhibits Hepatitis B virus replication by destabilizing viral RNA and negatively regulates the virus-induced innate inflammatory responses. Antiviral Res 2020;174:104705. [PMID: 31926181 DOI: 10.1016/j.antiviral.2020.104705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
38 Vyas AK, Jindal A, Trehanpati N. Ponder the Innate Immunity in Hepatitis B Infection. Gastroenterology 2018;155:1277. [PMID: 30222943 DOI: 10.1053/j.gastro.2018.05.052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Sharifian A. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. J Viral Hepat 2017;24:776-88. [DOI: 10.1111/jvh.12699] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Liu F, Campagna M, Qi Y, Zhao X, Guo F, Xu C, Li S, Li W, Block TM, Chang J, Guo JT. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog. 2013;9:e1003613. [PMID: 24068929 DOI: 10.1371/journal.ppat.1003613] [Cited by in Crossref: 107] [Cited by in F6Publishing: 95] [Article Influence: 13.4] [Reference Citation Analysis]
41 Kim HY, Jhun JY, Cho ML, Choi JY, Byun JK, Kim EK, Yoon SK, Bae SH, Chung BH, Yang CW. Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure. J Gastroenterol. 2014;49:1264-1273. [PMID: 24366287 DOI: 10.1007/s00535-013-0891-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
42 Tzeng HT, Hsu PN, Chen PJ. Immunocompetent nontransgenic mouse models for studying hepatitis B virus immune responses. J Gastroenterol Hepatol. 2013;28 Suppl 1:116-119. [PMID: 23855306 DOI: 10.1111/jgh.12035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
43 Yang K, Guan S, Zhang H, Chen Z. Induction of interleukin 6 impairs the anti-HBV efficiency of IFN-α in human hepatocytes through upregulation of SOCS3: YANG et al.. J Med Virol 2019;91:803-12. [DOI: 10.1002/jmv.25382] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
44 Zhao X, Sun L, Mu T, Yi J, Ma C, Xie H, Liu M, Tang H. An HBV-encoded miRNA activates innate immunity to restrict HBV replication. J Mol Cell Biol. 2020;12:263-276. [PMID: 31865380 DOI: 10.1093/jmcb/mjz104] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
45 Ait-Goughoulte M, Lucifora J, Zoulim F, Durantel D. Innate antiviral immune responses to hepatitis B virus. Viruses. 2010;2:1394-1410. [PMID: 21994686 DOI: 10.3390/v2071394] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.2] [Reference Citation Analysis]
46 Niu C, Livingston CM, Li L, Beran RK, Daffis S, Ramakrishnan D, Burdette D, Peiser L, Salas E, Ramos H, Yu M, Cheng G, Strubin M, Delaney WE IV, Fletcher SP. The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection. PLoS One. 2017;12:e0169648. [PMID: 28095508 DOI: 10.1371/journal.pone.0169648] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 15.5] [Reference Citation Analysis]
47 Xia Y, Protzer U. Control of Hepatitis B Virus by Cytokines. Viruses. 2017;9:18. [PMID: 28117695 DOI: 10.3390/v9010018] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 13.8] [Reference Citation Analysis]
48 Faure-Dupuy S, Delphin M, Aillot L, Dimier L, Lebossé F, Fresquet J, Parent R, Matter MS, Rivoire M, Bendriss-Vermare N, Salvetti A, Heide D, Flores L, Klumpp K, Lam A, Zoulim F, Heikenwälder M, Durantel D, Lucifora J. Hepatitis B virus-induced modulation of liver macrophage function promotes hepatocyte infection. J Hepatol 2019;71:1086-98. [PMID: 31349000 DOI: 10.1016/j.jhep.2019.06.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
49 Khatun M, Mondal RK, Pal S, Baidya A, Bishnu D, Banerjee P, Santra AK, Dhali GK, Banerjee S, Chowdhury A, Datta S. Distinctiveness in virological features and pathogenic potentials of subgenotypes D1, D2, D3 and D5 of Hepatitis B virus. Sci Rep. 2018;8:8055. [PMID: 29795338 DOI: 10.1038/s41598-018-26414-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
50 Takaki A, Yagi T, Yamamoto K. Contradictory immune response in post liver transplantation hepatitis B and C. Int J Inflam 2014;2014:814760. [PMID: 25215259 DOI: 10.1155/2014/814760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
51 Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258-4270. [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 52] [Article Influence: 5.4] [Reference Citation Analysis]
52 Cho O, Cheong JY, Jun KJ, Kim SS, Chwae YJ, Kim K, Park S, Cho SW. Relevance of interleukin-10RB to chronic hepatitis B virus infection and biological activities of interferon-λ and interleukin-22. Hepatol Int. 2013;7:111-118. [PMID: 23519428 DOI: 10.1007/s12072-012-9361-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
53 Yao Z, Jia X, Megger DA, Chen J, Liu Y, Li J, Sitek B, Yuan Z. Label-Free Proteomic Analysis of Exosomes Secreted from THP-1-Derived Macrophages Treated with IFN-α Identifies Antiviral Proteins Enriched in Exosomes. J Proteome Res 2019;18:855-64. [DOI: 10.1021/acs.jproteome.8b00514] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
54 Zhang Z, Trippler M, Real CI, Werner M, Luo X, Schefczyk S, Kemper T, Anastasiou OE, Ladiges Y, Treckmann J, Paul A, Baba HA, Allweiss L, Dandri M, Gerken G, Wedemeyer H, Schlaak JF, Lu M, Broering R. Hepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes. Hepatology 2020;72:829-44. [PMID: 31925967 DOI: 10.1002/hep.31112] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
55 Zhang X, Ma Z, Liu H, Liu J, Meng Z, Broering R, Yang D, Schlaak JF, Roggendorf M, Lu M. Role of Toll-like receptor 2 in the immune response against hepadnaviral infection. J Hepatol. 2012;57:522-528. [PMID: 22617154 DOI: 10.1016/j.jhep.2012.05.004] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 6.0] [Reference Citation Analysis]
56 Means S, Ali MA, Ho H, Heffernan J. Mathematical Modeling for Hepatitis B Virus: Would Spatial Effects Play a Role and How to Model It? Front Physiol 2020;11:146. [PMID: 32158403 DOI: 10.3389/fphys.2020.00146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Tang J, Wu ZY, Dai RJ, Ma J, Gong GZ. Hepatitis B virus-persistent infection and innate immunity defect: Cell-related or virus-related? World J Clin Cases 2018;6:233-41. [PMID: 30211203 DOI: 10.12998/wjcc.v6.i9.233] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
58 Fletcher SP, Chin DJ, Cheng DT, Ravindran P, Bitter H, Gruenbaum L, Cote PJ, Ma H, Klumpp K, Menne S. Identification of an intrahepatic transcriptional signature associated with self-limiting infection in the woodchuck model of hepatitis B. Hepatology. 2013;57:13-22. [PMID: 22806943 DOI: 10.1002/hep.25954] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.3] [Reference Citation Analysis]
59 Yong L, Li M, Gao Y, Deng Y, Liu W, Huang D, Ren C, Liu M, Shen J, Hou X. Identification of pro-inflammatory CD205+ macrophages in livers of hepatitis B virus transgenic mice and patients with chronic hepatitis B. Sci Rep 2017;7:46765. [PMID: 28436459 DOI: 10.1038/srep46765] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
60 Raghunath A, Sundarraj K, Arfuso F, Sethi G, Perumal E. Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance. Cancers (Basel) 2018;10:E481. [PMID: 30513925 DOI: 10.3390/cancers10120481] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 22.7] [Reference Citation Analysis]
61 Xu J, Zhan Q, Fan Y, Yu Y, Zeng Z. Human genetic susceptibility to hepatitis B virus infection. Infect Genet Evol 2021;87:104663. [PMID: 33278635 DOI: 10.1016/j.meegid.2020.104663] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
62 Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Fan JG. Saturated Fatty Acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon. 2015;15:e27909. [PMID: 26045709 DOI: 10.5812/hepatmon.15(5)2015.27909] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
63 Phipps C, Chen Y, Tan D. Lymphoproliferative Disease and Hepatitis B Reactivation: Challenges in the Era of Rapidly Evolving Targeted Therapy. Clin Lymphoma Myeloma Leuk 2016;16:5-11. [PMID: 26705677 DOI: 10.1016/j.clml.2015.11.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
64 Ligat G, Goto K, Verrier E, Baumert TF. Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Curr Hepatology Rep 2020;19:235-44. [DOI: 10.1007/s11901-020-00534-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
65 Jung J, Kim NK, Park S, Shin HJ, Hwang SG, Kim K. Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro. BMC Complement Altern Med. 2015;15:255. [PMID: 26220282 DOI: 10.1186/s12906-015-0792-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
66 Shi Y, Song Q, Hu D, Zhuang X, Yu S. Tumor-infiltrating lymphocyte activity is enhanced in tumors with low IL-10 production in HBV-induced hepatocellular carcinoma. Biochem Biophys Res Commun 2015;461:109-14. [PMID: 25862952 DOI: 10.1016/j.bbrc.2015.03.177] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
67 Li YX, Ren YL, Fu HJ, Zou L, Yang Y, Chen Z. Hepatitis B Virus Middle Protein Enhances IL-6 Production via p38 MAPK/NF-κB Pathways in an ER Stress-Dependent Manner. PLoS One 2016;11:e0159089. [PMID: 27434097 DOI: 10.1371/journal.pone.0159089] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
68 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
69 Shin GC, Ahn SH, Choi HS, Kim J, Park ES, Kim DH, Kim KH. Hepatocystin contributes to interferon-mediated antiviral response to hepatitis B virus by regulating hepatocyte nuclear factor 4α. Biochim Biophys Acta. 2014;1842:1648-1657. [PMID: 24769044 DOI: 10.1016/j.bbadis.2014.04.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
70 Takaki A, Yamamoto K. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J Hepatol 2015;7:968-79. [PMID: 25954479 DOI: 10.4254/wjh.v7.i7.968] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 9.5] [Reference Citation Analysis]
71 Broering R, Lu M, Schlaak JF. Role of Toll-like receptors in liver health and disease. Clin Sci (Lond). 2011;121:415-426. [PMID: 21797822 DOI: 10.1042/cs20110065] [Cited by in Crossref: 53] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
72 Ma Z, Liu J, Wu W, Zhang E, Zhang X, Li Q, Zelinskyy G, Buer J, Dittmer U, Kirschning CJ, Lu M. The IL-1R/TLR signaling pathway is essential for efficient CD8+ T-cell responses against hepatitis B virus in the hydrodynamic injection mouse model. Cell Mol Immunol 2017;14:997-1008. [PMID: 28757610 DOI: 10.1038/cmi.2017.43] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
73 Wu LL, Huang TS, Shyu YC, Wang CL, Wang HY, Chen PJ. Gut microbiota in the innate immunity against hepatitis B virus - implication in age-dependent HBV clearance. Curr Opin Virol 2021;49:194-202. [PMID: 34242953 DOI: 10.1016/j.coviro.2021.06.006] [Reference Citation Analysis]
74 Espíndola KMM, Ferreira RG, Narvaez LEM, Silva Rosario ACR, da Silva AHM, Silva AGB, Vieira APO, Monteiro MC. Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma. Front Oncol 2019;9:541. [PMID: 31293975 DOI: 10.3389/fonc.2019.00541] [Cited by in Crossref: 71] [Cited by in F6Publishing: 45] [Article Influence: 35.5] [Reference Citation Analysis]
75 Durantel D, Zoulim F. Innate response to hepatitis B virus infection: observations challenging the concept of a stealth virus. Hepatology 2009;50:1692-5. [PMID: 19937686 DOI: 10.1002/hep.23361] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
76 Pan CJ, Wu HL, Kuo SF, Kao JH, Tseng TC, Liu CH, Chen PJ, Liu CJ, Chen DS. Serum interleukin 6 level correlates with outcomes of acute exacerbation of chronic hepatitis B. Hepatol Int 2012;6:591-7. [PMID: 21769441 DOI: 10.1007/s12072-011-9299-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
77 Dou L, Shi X, He X, Gao Y. Macrophage Phenotype and Function in Liver Disorder. Front Immunol 2019;10:3112. [PMID: 32047496 DOI: 10.3389/fimmu.2019.03112] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
78 Pang J, Zhang G, Lin Y, Xie Z, Liu H, Tang L, Lu M, Yan R, Guo H, Sun J, Hou J, Zhang X. Transforming growth factor β-activated kinase 1 transcriptionally suppresses hepatitis B virus replication. Sci Rep 2017;7:39901. [PMID: 28045080 DOI: 10.1038/srep39901] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
79 Xu Y, Köck J, Lu Y, Yang D, Lu M, Zhao X. Suppression of hepatitis B virus replication in Tupaia hepatocytes by tumor necrosis factor alpha of Tupaia belangeri. Comp Immunol Microbiol Infect Dis 2011;34:361-8. [PMID: 21684599 DOI: 10.1016/j.cimid.2011.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
80 Luangsay S, Ait-Goughoulte M, Michelet M, Floriot O, Bonnin M, Gruffaz M, Rivoire M, Fletcher S, Javanbakht H, Lucifora J, Zoulim F, Durantel D. Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. J Hepatol. 2015;63:1077-1085. [PMID: 26144659 DOI: 10.1016/j.jhep.2015.06.022] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
81 Takaki A, Yasunaka T, Yagi T. Molecular Mechanisms to Control Post-Transplantation Hepatitis B Recurrence. Int J Mol Sci 2015;16:17494-513. [PMID: 26263973 DOI: 10.3390/ijms160817494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
82 Bouezzedine F, Fardel O, Gripon P. Interleukin 6 inhibits HBV entry through NTCP down regulation. Virology. 2015;481:34-42. [PMID: 25765005 DOI: 10.1016/j.virol.2015.02.026] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 8.3] [Reference Citation Analysis]
83 Moudi B, Heidari Z, Mahmoudzadeh-sagheb H. Impact of host gene polymorphisms on susceptibility to chronic hepatitis B virus infection. Infection, Genetics and Evolution 2016;44:94-105. [DOI: 10.1016/j.meegid.2016.06.043] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
84 Real CI, Lu M, Liu J, Huang X, Trippler M, Hossbach M, Deckert J, Jahn-Hofmann K, Ickenstein LM, John MJ. Hepatitis B virus genome replication triggers toll-like receptor 3-dependent interferon responses in the absence of hepatitis B surface antigen. Sci Rep. 2016;6:24865. [PMID: 27121087 DOI: 10.1038/srep24865] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
85 Wang Z, Li Z, Ye Y, Xie L, Li W. Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets. Oxid Med Cell Longev 2016;2016:7891574. [PMID: 27957239 DOI: 10.1155/2016/7891574] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 10.8] [Reference Citation Analysis]
86 Wang HJ, Jiang YF, Wang XR, Zhang ML, Gao PJ. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. World J Gastroenterol 2016;22:4529-37. [PMID: 27182162 DOI: 10.3748/wjg.v22.i18.4529] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
87 Lin YJ, Wu HL, Chen DS, Chen PJ. Hepatitis B virus nucleocapsid but not free core antigen controls viral clearance in mice. J Virol. 2012;86:9266-9273. [PMID: 22718814 DOI: 10.1128/jvi.00608-12] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
88 Liu J, Yu Q, Wu W, Huang X, Broering R, Werner M, Roggendorf M, Yang D, Lu M. TLR2 Stimulation Strengthens Intrahepatic Myeloid-Derived Cell-Mediated T Cell Tolerance through Inducing Kupffer Cell Expansion and IL-10 Production. J Immunol. 2018;200:2341-2351. [PMID: 29459406 DOI: 10.4049/jimmunol.1700540] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
89 Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, Kleiner DE, Deeks SG, Liang TJ, Heller T. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology. 2011;141:1220-1230, 1230.e1-1230.e3. [PMID: 21726511 DOI: 10.1053/j.gastro.2011.06.063] [Cited by in Crossref: 196] [Cited by in F6Publishing: 187] [Article Influence: 19.6] [Reference Citation Analysis]
90 Ebrahim M, Bagheri V, Arababadi MK. Potential roles played by IL-6 in hepatitis B infection. Future Virology 2014;9:431-8. [DOI: 10.2217/fvl.14.21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.1] [Reference Citation Analysis]
91 Boltjes A, Movita D, Boonstra A, Woltman AM. The role of Kupffer cells in hepatitis B and hepatitis C virus infections. J Hepatol. 2014;61:660-671. [PMID: 24798624 DOI: 10.1016/j.jhep.2014.04.026] [Cited by in Crossref: 99] [Cited by in F6Publishing: 84] [Article Influence: 14.1] [Reference Citation Analysis]
92 Feustel S, Ayón-Pérez F, Sandoval-Rodriguez A, Rodríguez-Echevarría R, Contreras-Salinas H, Armendáriz-Borunda J, Sánchez-Orozco LV. Protective Effects of Moringa oleifera on HBV Genotypes C and H Transiently Transfected Huh7 Cells. J Immunol Res 2017;2017:6063850. [PMID: 29214184 DOI: 10.1155/2017/6063850] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
93 Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY, Lee CH, Lai NS. Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment. Dig Dis Sci. 2021;. [PMID: 33387124 DOI: 10.1007/s10620-020-06725-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Chen H, He G, Chen Y, Zhang X. Hepatitis B Virus Might Be Sensed by STING-Dependent DNA Sensors and Attenuates the Response of STING-Dependent DNA Sensing Pathway in Humans with Acute and Chronic Hepatitis B Virus Infection. Viral Immunol 2020;33:642-51. [PMID: 33170089 DOI: 10.1089/vim.2020.0096] [Reference Citation Analysis]
95 Suslov A, Wieland S, Menne S. Modulators of innate immunity as novel therapeutics for treatment of chronic hepatitis B. Curr Opin Virol. 2018;30:9-17. [PMID: 29444493 DOI: 10.1016/j.coviro.2018.01.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
96 Wu J, Han M, Li J, Yang X, Yang D. Immunopathogenesis of HBV Infection. In: Tang H, editor. Hepatitis B Virus Infection. Singapore: Springer; 2020. pp. 71-107. [DOI: 10.1007/978-981-13-9151-4_4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
97 Liu D, Wu A, Cui L, Hao R, Wang Y, He J, Guo D. Hepatitis B virus polymerase suppresses NF-κB signaling by inhibiting the activity of IKKs via interaction with Hsp90β. PLoS One. 2014;9:e91658. [PMID: 24618592 DOI: 10.1371/journal.pone.0091658] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
98 Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 2018;67:542-52. [PMID: 28428345 DOI: 10.1136/gutjnl-2016-312162] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 19.8] [Reference Citation Analysis]
99 Broering R, Luo X, Liu J, Lu M. Controversial: Early Innate Responses to Hepatitis B Virus Infection, an Explanation for Viral Persistence? Virol Sin 2021;36:163-6. [PMID: 32632817 DOI: 10.1007/s12250-020-00235-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Isorce N, Lucifora J, Zoulim F, Durantel D. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies. Antiviral Res. 2015;122:69-81. [PMID: 26275801 DOI: 10.1016/j.antiviral.2015.08.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 7.0] [Reference Citation Analysis]
101 Zhao XM, Gao YF, Zhou Q, Pan FM, Li X. Relationship between interleukin-6 polymorphism and susceptibility to chronic hepatitis B virus infection. World J Gastroenterol 2013;19:6888-93. [PMID: 24187466 DOI: 10.3748/wjg.v19.i40.6888] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
102 Tan A, Koh S, Bertoletti A. Immune Response in Hepatitis B Virus Infection. Cold Spring Harb Perspect Med. 2015;5:a021428. [PMID: 26134480 DOI: 10.1101/cshperspect.a021428] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 6.7] [Reference Citation Analysis]
103 Liu H, Lou G, Li C, Wang X, Cederbaum AI, Gan L, Xie B. HBx inhibits CYP2E1 gene expression via downregulating HNF4α in human hepatoma cells. PLoS One 2014;9:e107913. [PMID: 25238230 DOI: 10.1371/journal.pone.0107913] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
104 Wang S, Chen Y, Xu X, Hu W, Shen H, Chen J. Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Oncotarget 2017;8:102437-45. [PMID: 29254259 DOI: 10.18632/oncotarget.22261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
105 Protzer U, Abken H. Can engineered "designer" T cells outsmart chronic hepatitis B? Hepat Res Treat 2010;2010:901216. [PMID: 21188203 DOI: 10.1155/2010/901216] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
106 Liu C, Huang X, Werner M, Broering R, Ge J, Li Y, Liao B, Sun J, Peng J, Lu M, Hou J, Zhang X. Elevated Expression of Chemokine CXCL13 in Chronic Hepatitis B Patients Links to Immune Control during Antiviral Therapy. Front Immunol 2017;8:323. [PMID: 28386259 DOI: 10.3389/fimmu.2017.00323] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
107 Palumbo GA, Scisciani C, Pediconi N, Lupacchini L, Alfalate D, Guerrieri F, Calvo L, Salerno D, Di Cocco S, Levrero M, Belloni L. IL6 Inhibits HBV Transcription by Targeting the Epigenetic Control of the Nuclear cccDNA Minichromosome. PLoS One 2015;10:e0142599. [PMID: 26580974 DOI: 10.1371/journal.pone.0142599] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
108 Zhang M, Zhao J, Tang W, Wang Y, Peng P, Li L, Song S, Wu H, Li C, Yang C, Wang X, Zhang C, Gu J. High Hepsin expression predicts poor prognosis in Gastric Cancer. Sci Rep 2016;6:36902. [PMID: 27841306 DOI: 10.1038/srep36902] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
109 Wu W, Dietze KK, Gibbert K, Lang KS, Trilling M, Yan H, Wu J, Yang D, Lu M, Roggendorf M, Dittmer U, Liu J. TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection. Sci Rep 2015;5:10501. [PMID: 25994622 DOI: 10.1038/srep10501] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
110 Zhang E, Lu M. Toll-like receptor (TLR)-mediated innate immune responses in the control of hepatitis B virus (HBV) infection. Med Microbiol Immunol. 2015;204:11-20. [PMID: 25550115 DOI: 10.1007/s00430-014-0370-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 8.9] [Reference Citation Analysis]
111 Gehring AJ, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. Gastroenterology. 2019;156:325-337. [PMID: 30367834 DOI: 10.1053/j.gastro.2018.10.032] [Cited by in Crossref: 60] [Cited by in F6Publishing: 55] [Article Influence: 20.0] [Reference Citation Analysis]
112 Leong CR, Oshiumi H, Suzuki T, Matsumoto M, Seya T. Nucleic Acid Sensors Involved in the Recognition of HBV in the Liver-Specific in vivo Transfection Mouse Models-Pattern Recognition Receptors and Sensors for HBV. Med Sci (Basel) 2015;3:16-24. [PMID: 29083388 DOI: 10.3390/medsci3020016] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
113 Li Y, Yao M, Duan X, Ye H, Li S, Chen L, Yang C, Chen Y. The USP18 cysteine protease promotes HBV production independent of its protease activity. Virol J 2020;17:47. [PMID: 32248821 DOI: 10.1186/s12985-020-01304-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Golsaz-Shirazi F, Shokri F. Hepatitis B immunopathogenesis and immunotherapy. Immunotherapy. 2016;8:461-477. [PMID: 26973127 DOI: 10.2217/imt.16.3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
115 Xu J, Gu W, Li C, Li X, Xing G, Li Y, Song Y, Zheng W. Epigallocatechin gallate inhibits hepatitis B virus via farnesoid X receptor alpha. J Nat Med 2016;70:584-91. [PMID: 26968537 DOI: 10.1007/s11418-016-0980-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.6] [Reference Citation Analysis]
116 Cui X, Clark DN, Liu K, Xu XD, Guo JT, Hu J. Viral DNA-Dependent Induction of Innate Immune Response to Hepatitis B Virus in Immortalized Mouse Hepatocytes. J Virol 2016;90:486-96. [PMID: 26491170 DOI: 10.1128/JVI.01263-15] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
117 Luangsay S, Gruffaz M, Isorce N, Testoni B, Michelet M, Faure-Dupuy S, Maadadi S, Ait-Goughoulte M, Parent R, Rivoire M, Javanbakht H, Lucifora J, Durantel D, Zoulim F. Early inhibition of hepatocyte innate responses by hepatitis B virus. J Hepatol. 2015;63:1314-1322. [PMID: 26216533 DOI: 10.1016/j.jhep.2015.07.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 13.3] [Reference Citation Analysis]
118 Luedde T, Schwabe RF. NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2011;8:108-18. [PMID: 21293511 DOI: 10.1038/nrgastro.2010.213] [Cited by in Crossref: 673] [Cited by in F6Publishing: 616] [Article Influence: 67.3] [Reference Citation Analysis]
119 Deng F, Xu G, Cheng Z, Huang Y, Ma C, Luo C, Yu C, Wang J, Xu X, Liu S, Zhu Y. Hepatitis B Surface Antigen Suppresses the Activation of Nuclear Factor Kappa B Pathway via Interaction With the TAK1-TAB2 Complex. Front Immunol 2021;12:618196. [PMID: 33717111 DOI: 10.3389/fimmu.2021.618196] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Ou Q, Guo J, Zeng Y, Chen H. Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection. J Viral Hepat 2020;27:224-32. [PMID: 31954089 DOI: 10.1111/jvh.13260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Cheng X, Xia Y, Serti E, Block PD, Chung M, Chayama K, Rehermann B, Liang TJ. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology. 2017;66:1779-1793. [PMID: 28665004 DOI: 10.1002/hep.29348] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 20.5] [Reference Citation Analysis]
122 Chen LF, Mo YQ, Jing J, Ma JD, Zheng DH, Dai L. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis. 2017;20:859-869. [PMID: 28160426 DOI: 10.1111/1756-185x.13010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 24] [Article Influence: 11.8] [Reference Citation Analysis]
123 Wu L, Wang W, Zhang X, Zhao X, Yu G. Anti-HBV activity and mechanism of marine-derived polyguluronate sulfate (PGS) in vitro. Carbohydrate Polymers 2016;143:139-48. [DOI: 10.1016/j.carbpol.2016.01.065] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
124 Wang W, Bian H, Li F, Li X, Zhang D, Sun S, Song S, Zhu Q, Ren W, Qin C, Qi J. HBeAg induces the expression of macrophage miR-155 to accelerate liver injury via promoting production of inflammatory cytokines. Cell Mol Life Sci 2018;75:2627-41. [PMID: 29349567 DOI: 10.1007/s00018-018-2753-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
125 Sghaier I, Mouelhi L, Ghazoueni E, Brochot E, Almawi WY, Yacoubi-Loueslati B. Role of TLRs and IL-6 in the outcome of chronic hepatitis C treatment in Tunisian population. Cytokine 2017;99:297-304. [PMID: 28823914 DOI: 10.1016/j.cyto.2017.08.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
126 Chang K. Hepatitis B Immunology for Clinicians. Clinics in Liver Disease 2010;14:409-24. [DOI: 10.1016/j.cld.2010.05.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
127 Campos-Valdez M, Monroy-Ramírez HC, Armendáriz-Borunda J, Sánchez-Orozco LV. Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability. Viruses 2021;13:1167. [PMID: 34207116 DOI: 10.3390/v13061167] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Zoulim F, Luangsay S, Durantel D. Targeting Innate Immunity: A New Step in the Development of Combination Therapy for Chronic Hepatitis B. Gastroenterology 2013;144:1342-4. [DOI: 10.1053/j.gastro.2013.04.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
129 Chang J, Block TM, Guo J. The innate immune response to hepatitis B virus infection: Implications for pathogenesis and therapy. Antiviral Research 2012;96:405-13. [DOI: 10.1016/j.antiviral.2012.10.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
130 Maini MK, Gehring AJ. The role of innate immunity in the immunopathology and treatment of HBV infection. J Hepatol. 2016;64:S60-S70. [PMID: 27084038 DOI: 10.1016/j.jhep.2016.01.028] [Cited by in Crossref: 92] [Cited by in F6Publishing: 87] [Article Influence: 23.0] [Reference Citation Analysis]
131 Ma Z, Cao Q, Xiong Y, Zhang E, Lu M. Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. Vaccines (Basel) 2018;6:E6. [PMID: 29337856 DOI: 10.3390/vaccines6010006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
132 Chen Y, Yang S, Chen D. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. Journal of Microbiology, Immunology and Infection 2019;52:1-8. [DOI: 10.1016/j.jmii.2017.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
133 Hayes CN, Zhang Y, Makokha GN, Hasan MZ, Omokoko MD, Chayama K. Early events in hepatitis B virus infection: From the cell surface to the nucleus. J Gastroenterol Hepatol 2016;31:302-9. [PMID: 26414381 DOI: 10.1111/jgh.13175] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
134 Yeo ECF, Brown MP, Gargett T, Ebert LM. The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy. Cells 2021;10:607. [PMID: 33803414 DOI: 10.3390/cells10030607] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Ortega-Prieto AM, Skelton JK, Wai SN, Large E, Lussignol M, Vizcay-Barrena G, Hughes D, Fleck RA, Thursz M, Catanese MT, Dorner M. 3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection. Nat Commun 2018;9:682. [PMID: 29445209 DOI: 10.1038/s41467-018-02969-8] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 31.3] [Reference Citation Analysis]
136 Wang F, Shen F, Wang Y, Li Z, Chen J, Yuan Z. Residues Asn118 and Glu119 of hepatitis B virus X protein are critical for HBx-mediated inhibition of RIG-I-MAVS signaling. Virology 2020;539:92-103. [PMID: 31706164 DOI: 10.1016/j.virol.2019.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
137 Kiziltas S. Toll-like receptors in pathophysiology of liver diseases. World J Hepatol. 2016;8:1354-1369. [PMID: 27917262 DOI: 10.4254/wjh.v8.i32.1354] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 11.0] [Reference Citation Analysis]
138 Yuen MF, Chen DS, Dusheiko GM, Janssen HLA, Lau DTY, Locarnini SA, Peters MG, Lai CL. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. [PMID: 29877316 DOI: 10.1038/nrdp.2018.35] [Cited by in Crossref: 172] [Cited by in F6Publishing: 140] [Article Influence: 57.3] [Reference Citation Analysis]
139 Bai L, Nong Y, Shi Y, Liu M, Yan L, Shang J, Huang F, Lin Y, Tang H. Luteolin Inhibits Hepatitis B Virus Replication through Extracellular Signal-Regulated Kinase-Mediated Down-Regulation of Hepatocyte Nuclear Factor 4α Expression. Mol Pharm 2016;13:568-77. [PMID: 26656210 DOI: 10.1021/acs.molpharmaceut.5b00789] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
140 Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012;12:201-13. [PMID: 22362353 DOI: 10.1038/nri3169] [Cited by in Crossref: 322] [Cited by in F6Publishing: 295] [Article Influence: 35.8] [Reference Citation Analysis]
141 Jung S, Altstetter SM, Protzer U. Innate immune recognition and modulation in hepatitis D virus infection. World J Gastroenterol 2020;26:2781-91. [PMID: 32550754 DOI: 10.3748/wjg.v26.i21.2781] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
142 Svinarenko M, Katz SF, Tharehalli U, Mulaw MA, Maier HJ, Sunami Y, Fischer SK, Chen Y, Heurich S, Erkert L, Tannapfel A, Wirth T, Schirmbeck R, Seufferlein T, Lechel A. An IKK/NF-κB Activation/p53 Deletion Sequence Drives Liver Carcinogenesis and Tumor Differentiation. Cancers (Basel) 2019;11:E1410. [PMID: 31546614 DOI: 10.3390/cancers11101410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
143 Rose-john S, Winthrop K, Calabrese L. The role of IL-6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol 2017;13:399-409. [DOI: 10.1038/nrrheum.2017.83] [Cited by in Crossref: 150] [Cited by in F6Publishing: 128] [Article Influence: 37.5] [Reference Citation Analysis]
144 Tzeng HT, Tsai HF, Chyuan IT, Liao HJ, Chen CJ, Chen PJ, Hsu PN. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS One. 2014;9:e103008. [PMID: 25047809 DOI: 10.1371/journal.pone.0103008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
145 Shirvani-Dastgerdi E, Schwartz RE, Ploss A. Hepatocarcinogenesis associated with hepatitis B, delta and C viruses. Curr Opin Virol 2016;20:1-10. [PMID: 27504999 DOI: 10.1016/j.coviro.2016.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
146 Hösel M, Quasdorff M, Ringelhan M, Kashkar H, Debey-Pascher S, Sprinzl MF, Bockmann JH, Arzberger S, Webb D, von Olshausen G, Weber A, Schultze JL, Büning H, Heikenwalder M, Protzer U. Hepatitis B Virus Activates Signal Transducer and Activator of Transcription 3 Supporting Hepatocyte Survival and Virus Replication. Cell Mol Gastroenterol Hepatol 2017;4:339-63. [PMID: 28884137 DOI: 10.1016/j.jcmgh.2017.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
147 Krepstakies M, Lucifora J, Nagel CH, Zeisel MB, Holstermann B, Hohenberg H, Kowalski I, Gutsmann T, Baumert TF, Brandenburg K, Hauber J, Protzer U. A new class of synthetic peptide inhibitors blocks attachment and entry of human pathogenic viruses. J Infect Dis. 2012;205:1654-1664. [PMID: 22457281 DOI: 10.1093/infdis/jis273] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
148 Li Y, Li S, Duan X, Yang C, Xu M, Chen L. Macrophage Phenotypes and Hepatitis B Virus Infection. J Clin Transl Hepatol. 2020;8:424-431. [PMID: 33447526 DOI: 10.14218/jcth.2020.00046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
149 Liu X, Wu Y, Yang Y, Li W, Huang C, Meng X, Li J. Role of NLRC5 in progression and reversal of hepatic fibrosis. Toxicology and Applied Pharmacology 2016;294:43-53. [DOI: 10.1016/j.taap.2016.01.012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
150 Roohani S, Tacke F. Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance. Int J Mol Sci 2021;22:7249. [PMID: 34298870 DOI: 10.3390/ijms22147249] [Reference Citation Analysis]
151 Stamataki Z, Swadling L. The liver as an immunological barrier redefined by single-cell analysis. Immunology 2020;160:157-70. [PMID: 32176810 DOI: 10.1111/imm.13193] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
152 Warshow UM, Riva A, Hegazy D, Thurairajah PH, Kaminski E, Chokshi S, Cramp ME. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection: Cytokine profiles in IDU. Journal of Viral Hepatitis 2012;19:501-8. [DOI: 10.1111/j.1365-2893.2011.01574.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
153 Duriez M, Mandouri Y, Lekbaby B, Wang H, Schnuriger A, Redelsperger F, Guerrera CI, Lefevre M, Fauveau V, Ahodantin J, Quetier I, Chhuon C, Gourari S, Boissonnas A, Gill U, Kennedy P, Debzi N, Sitterlin D, Maini MK, Kremsdorf D, Soussan P. Alternative splicing of hepatitis B virus: A novel virus/host interaction altering liver immunity. J Hepatol 2017;67:687-99. [PMID: 28600137 DOI: 10.1016/j.jhep.2017.05.025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
154 Hösel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, Gillen S, Kleeff J, Stabenow D, Odenthal M. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology. 2012;55:287-297. [PMID: 21898480 DOI: 10.1002/hep.24625] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 10.0] [Reference Citation Analysis]
155 Isorce N, Testoni B, Locatelli M, Fresquet J, Rivoire M, Luangsay S, Zoulim F, Durantel D. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res. 2016;130:36-45. [PMID: 26971407 DOI: 10.1016/j.antiviral.2016.03.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 7.8] [Reference Citation Analysis]
156 Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. PLoS One 2011;6:e15324. [PMID: 21246041 DOI: 10.1371/journal.pone.0015324] [Cited by in Crossref: 95] [Cited by in F6Publishing: 94] [Article Influence: 9.5] [Reference Citation Analysis]
157 Li G, Zhu Y, Shao D, Chang H, Zhang X, Zhou D, Gao Y, Lan K, Deng Q. Recombinant covalently closed circular DNA of hepatitis B virus induces long-term viral persistence with chronic hepatitis in a mouse model. Hepatology 2018;67:56-70. [DOI: 10.1002/hep.29406] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 6.5] [Reference Citation Analysis]
158 Boltjes A, van Montfoort N, Biesta PJ, Op den Brouw ML, Kwekkeboom J, van der Laan LJ, Janssen HL, Boonstra A, Woltman AM. Kupffer cells interact with hepatitis B surface antigen in vivo and in vitro, leading to proinflammatory cytokine production and natural killer cell function. J Infect Dis. 2015;211:1268-1278. [PMID: 25362194 DOI: 10.1093/infdis/jiu599] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
159 Megahed FAK, Zhou X, Sun P. The Interactions between HBV and the Innate Immunity of Hepatocytes. Viruses 2020;12:E285. [PMID: 32151000 DOI: 10.3390/v12030285] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 14.0] [Reference Citation Analysis]
160 Thomsen MK, Nandakumar R, Stadler D, Malo A, Valls RM, Wang F, Reinert LS, Dagnaes-Hansen F, Hollensen AK, Mikkelsen JG. Lack of immunological DNA sensing in hepatocytes facilitates hepatitis B virus infection. Hepatology. 2016;64:746-759. [PMID: 27312012 DOI: 10.1002/hep.28685] [Cited by in Crossref: 71] [Cited by in F6Publishing: 71] [Article Influence: 14.2] [Reference Citation Analysis]
161 Zhang F, Yao S, Zhang M, Yuan J, Chen X, Zhou B. Roles of circulating soluble interleukin (IL)-6 receptor and IL-6 receptor expression on CD4+ T cells in patients with chronic hepatitis B. Int J Infect Dis 2011;15:e267-71. [PMID: 21295508 DOI: 10.1016/j.ijid.2010.12.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
162 Dusséaux M, Masse-Ranson G, Darche S, Ahodantin J, Li Y, Fiquet O, Beaumont E, Moreau P, Rivière L, Neuveut C, Soussan P, Roingeard P, Kremsdorf D, Di Santo JP, Strick-Marchand H. Viral Load Affects the Immune Response to HBV in Mice With Humanized Immune System and Liver. Gastroenterology 2017;153:1647-1661.e9. [PMID: 28851562 DOI: 10.1053/j.gastro.2017.08.034] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 9.8] [Reference Citation Analysis]
163 Faure-Dupuy S, Lucifora J, Durantel D. Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. Viruses 2017;9:E95. [PMID: 28452930 DOI: 10.3390/v9050095] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
164 Fletcher SP, Chin DJ, Ji Y, Iniguez AL, Taillon B, Swinney DC, Ravindran P, Cheng DT, Bitter H, Lopatin U, Ma H, Klumpp K, Menne S. Transcriptomic analysis of the woodchuck model of chronic hepatitis B. Hepatology. 2012;56:820-830. [PMID: 22431061 DOI: 10.1002/hep.25730] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 8.1] [Reference Citation Analysis]
165 Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol. 2016;64:1403-1415. [PMID: 26867490 DOI: 10.1016/j.jhep.2016.02.004] [Cited by in Crossref: 305] [Cited by in F6Publishing: 271] [Article Influence: 61.0] [Reference Citation Analysis]
166 Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat. 2010;17:527-536. [PMID: 20546497 DOI: 10.1111/j.1365-2893.2010.01315.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 125] [Article Influence: 11.5] [Reference Citation Analysis]
167 Lin J, Wu JF, Zhang Q, Zhang HW, Cao GW. Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol 2014;20:6457-69. [PMID: 24914367 DOI: 10.3748/wjg.v20.i21.6457] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
168 Park YK, Park ES, Kim DH, Ahn SH, Park SH, Lee AR, Park S, Kang HS, Lee JH, Kim JM. Cleaved c-FLIP mediates the antiviral effect of TNF-α against hepatitis B virus by dysregulating hepatocyte nuclear factors. J Hepatol. 2016;64:268-277. [PMID: 26409214 DOI: 10.1016/j.jhep.2015.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
169 Burton AR, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. J Clin Invest. 2018;128:4588-4603. [PMID: 30091725 DOI: 10.1172/jci121960] [Cited by in Crossref: 103] [Cited by in F6Publishing: 57] [Article Influence: 34.3] [Reference Citation Analysis]
170 Quasdorff M, Protzer U. Control of hepatitis B virus at the level of transcription. J Viral Hepat. 2010;17:527-536. [PMID: 20546497 DOI: 510.1111/j.1365-2893.2010.01315.x] [Reference Citation Analysis]
171 Asín-Prieto E, Parra-Guillen ZP, Mantilla JDG, Vandenbossche J, Stuyckens K, de Trixhe XW, Perez-Ruixo JJ, Troconiz IF. Immune network for viral hepatitis B: Topological representation. Eur J Pharm Sci 2019;136:104939. [PMID: 31195071 DOI: 10.1016/j.ejps.2019.05.017] [Reference Citation Analysis]
172 He D, Li M, Guo S, Zhu P, Huang H, Yan G, Wu Q, Tao S, Tan Z, Wang Y. Expression pattern of serum cytokines in hepatitis B virus infected patients with persistently normal alanine aminotransferase levels. J Clin Immunol 2013;33:1240-9. [PMID: 23954997 DOI: 10.1007/s10875-013-9931-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
173 Hayes CN, Chayama K. Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses: ISGs in HCV and HBV Infection. J Med Virol 2017;89:388-96. [DOI: 10.1002/jmv.24659] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
174 Kanda M, Sugimoto H, Kodera Y. Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol. 2015;21:10584-10597. [PMID: 26457018 DOI: 10.3748/wjg.v21.i37.10584] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 41] [Article Influence: 7.4] [Reference Citation Analysis]
175 Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. J Virol. 2011;85:987-995. [PMID: 21068253 DOI: 10.1128/jvi.01825-10] [Cited by in Crossref: 88] [Cited by in F6Publishing: 51] [Article Influence: 8.0] [Reference Citation Analysis]
176 Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin Drug Discov. 2012;7:597-611. [PMID: 22607384 DOI: 10.1517/17460441.2012.689281] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
177 Li M, Zhuo Y, Xu Y, Chen H, Cheng Z, Zhou L. Genetic Association of Interleukin-6 Polymorphism (rs1800796) with Chronic Hepatitis B Virus Infection in Chinese Han Population. Viral Immunol 2021;34:267-72. [PMID: 33305999 DOI: 10.1089/vim.2020.0211] [Reference Citation Analysis]
178 Felis-Giemza A, Olesińska M, Świerkocka K, Więsik-Szewczyk E, Haładyj E. Treatment of rheumatic diseases and hepatitis B virus coinfection. Rheumatol Int 2015;35:385-92. [PMID: 25549599 DOI: 10.1007/s00296-014-3195-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
179 Ferrari C. HBV and the immune response. Liver Int. 2015;35 Suppl 1:121-128. [PMID: 25529097 DOI: 10.1111/liv.12749] [Cited by in Crossref: 105] [Cited by in F6Publishing: 92] [Article Influence: 17.5] [Reference Citation Analysis]
180 Han YF, Zhao J, Ma LY, Yin JH, Chang WJ, Zhang HW, Cao GW. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol. 2011;17:4258-4270. [PMID: 22090781 DOI: 10.3748/wjg.v17.i38.4258.] [Reference Citation Analysis]
181 Lucifora J, Bonnin M, Aillot L, Fusil F, Maadadi S, Dimier L, Michelet M, Floriot O, Ollivier A, Rivoire M, Ait-Goughoulte M, Daffis S, Fletcher SP, Salvetti A, Cosset FL, Zoulim F, Durantel D. Direct antiviral properties of TLR ligands against HBV replication in immune-competent hepatocytes. Sci Rep 2018;8:5390. [PMID: 29599452 DOI: 10.1038/s41598-018-23525-w] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
182 Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017;9:156. [PMID: 28635668 DOI: 10.3390/v9060156] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
183 Ganesan M, Eikenberry A, Poluektova LY, Kharbanda KK, Osna NA. Role of alcohol in pathogenesis of hepatitis B virus infection. World J Gastroenterol 2020;26:883-903. [PMID: 32206001 DOI: 10.3748/wjg.v26.i9.883] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
184 Dondeti MF, El-Maadawy EA, Talaat RM. Hepatitis-related hepatocellular carcinoma: Insights into cytokine gene polymorphisms. World J Gastroenterol 2016;22:6800-16. [PMID: 27570418 DOI: 10.3748/wjg.v22.i30.6800] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
185 Lang T, Lo C, Skinner N, Locarnini S, Visvanathan K, Mansell A. The hepatitis B e antigen (HBeAg) targets and suppresses activation of the toll-like receptor signaling pathway. J Hepatol. 2011;55:762-769. [PMID: 21334391 DOI: 10.1016/j.jhep.2010.12.042] [Cited by in Crossref: 126] [Cited by in F6Publishing: 115] [Article Influence: 12.6] [Reference Citation Analysis]
186 Fergusson JR, Wallace Z, Connolly MM, Woon AP, Suckling RJ, Hine DW, Barber C, Bunjobpol W, Choi BS, Crespillo S, Dembek M, Dieckmann N, Donoso J, Godinho LF, Grant T, Howe D, McCully ML, Perot C, Sarkar A, Seifert FU, Singh PK, Stegmann KA, Turner B, Verma A, Walker A, Leonard S, Maini MK, Wiederhold K, Dorrell L, Simmons R, Knox A. Immune-Mobilizing Monoclonal T Cell Receptors Mediate Specific and Rapid Elimination of Hepatitis B-Infected Cells. Hepatology. 2020;72:1528-1540. [PMID: 32770836 DOI: 10.1002/hep.31503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
187 Hu J, Protzer U, Siddiqui A. Revisiting Hepatitis B Virus: Challenges of Curative Therapies. J Virol 2019;93:e01032-19. [PMID: 31375584 DOI: 10.1128/JVI.01032-19] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
188 Bengsch B, Chang KM. Evolution in Our Understanding of Hepatitis B Virus Virology and Immunology. Clin Liver Dis 2016;20:629-44. [PMID: 27742004 DOI: 10.1016/j.cld.2016.06.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
189 Zannetti C, Roblot G, Charrier E, Ainouze M, Tout I, Briat F, Isorce N, Faure-Dupuy S, Michelet M, Marotel M, Kati S, Schulz TF, Rivoire M, Traverse-Glehen A, Luangsay S, Alatiff O, Henry T, Walzer T, Durantel D, Hasan U. Characterization of the Inflammasome in Human Kupffer Cells in Response to Synthetic Agonists and Pathogens. J Immunol. 2016;197:356-367. [PMID: 27226092 DOI: 10.4049/jimmunol.1502301] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
190 Han Y, Gu L, Liu J, Li X, Wang M, Gong Q, Yu D, Yang Z, Zhang D, Yang H, Shen Z, Zhu H, Xie Y, Zhang X. Association of Mutations in Toll-like Receptor 2 Signaling Genes With Fulminant Form of Hepatitis B-Related Acute Liver Failure. J Infect Dis 2017;215:1221-30. [PMID: 28329297 DOI: 10.1093/infdis/jix097] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
191 Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA--The holy grail to hepatitis B cure. J Hepatol. 2016;64:S41-S48. [PMID: 27084036 DOI: 10.1016/j.jhep.2016.02.009] [Cited by in Crossref: 95] [Cited by in F6Publishing: 82] [Article Influence: 23.8] [Reference Citation Analysis]
192 Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T. Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID). J Biol Chem. 2013;288:31715-31727. [PMID: 24025329 DOI: 10.1074/jbc.m113.50112] [Reference Citation Analysis]
193 Dong J, Ying J, Qiu X, Lu Y, Zhang M. Advanced Strategies for Eliminating the cccDNA of HBV. Dig Dis Sci 2018;63:7-15. [PMID: 29159681 DOI: 10.1007/s10620-017-4842-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
194 Zhao Z, Hong W, Zeng Z, Wu Y, Hu K, Tian X, Li W, Cao Z. Mucroporin-M1 inhibits hepatitis B virus replication by activating the mitogen-activated protein kinase (MAPK) pathway and down-regulating HNF4α in vitro and in vivo. J Biol Chem 2012;287:30181-90. [PMID: 22791717 DOI: 10.1074/jbc.M112.370312] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
195 Ligat G, Verrier ER, Nassal M, Baumert TF. Hepatitis B virus-host interactions and novel targets for viral cure. Curr Opin Virol 2021;49:41-51. [PMID: 34029994 DOI: 10.1016/j.coviro.2021.04.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
196 Liu Y, Li J, Chen J, Li Y, Wang W, Du X, Song W, Zhang W, Lin L, Yuan Z. Hepatitis B virus polymerase disrupts K63-linked ubiquitination of STING to block innate cytosolic DNA-sensing pathways. J Virol. 2015;89:2287-2300. [PMID: 25505063 DOI: 10.1128/jvi.02760-14] [Cited by in Crossref: 111] [Cited by in F6Publishing: 79] [Article Influence: 15.9] [Reference Citation Analysis]
197 Tan-Garcia A, Wai LE, Zheng D, Ceccarello E, Jo J, Banu N, Khakpoor A, Chia A, Tham CYL, Tan AT. Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease. J Hepatol. 2017;67:490-500. [PMID: 28483682 DOI: 10.1016/j.jhep.2017.04.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 8.0] [Reference Citation Analysis]
198 Li S, Li H, Xu X, Saw PE, Zhang L. Nanocarrier-mediated antioxidant delivery for liver diseases. Theranostics 2020;10:1262-80. [PMID: 31938064 DOI: 10.7150/thno.38834] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
199 Park Y, Park Y, Han KH, Kim HS. Serum cytokine levels in patients with chronic hepatitis B according to lamivudine therapy. J Clin Lab Anal. 2011;25:414-421. [PMID: 22086795 DOI: 10.1002/jcla.20495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
200 Bockmann JH, Stadler D, Xia Y, Ko C, Wettengel JM, Schulze Zur Wiesch J, Dandri M, Protzer U. Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes. J Infect Dis. 2019;220:567-577. [PMID: 30923817 DOI: 10.1093/infdis/jiz143] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
201 Han Q, Zhang C, Zhang J, Tian Z. Involvement of activation of PKR in HBx-siRNA-mediated innate immune effects on HBV inhibition. PLoS One 2011;6:e27931. [PMID: 22174754 DOI: 10.1371/journal.pone.0027931] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
202 Mao R, Nie H, Cai D, Zhang J, Liu H, Yan R, Cuconati A, Block TM, Guo JT, Guo H. Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein. PLoS Pathog. 2013;9:e1003494. [PMID: 23853601 DOI: 10.1371/journal.ppat.1003494] [Cited by in Crossref: 135] [Cited by in F6Publishing: 125] [Article Influence: 16.9] [Reference Citation Analysis]
203 Robertson CL, Srivastava J, Siddiq A, Gredler R, Emdad L, Rajasekaran D, Akiel M, Shen XN, Guo C, Giashuddin S. Genetic deletion of AEG-1 prevents hepatocarcinogenesis. Cancer Res. 2014;74:6184-6193. [PMID: 25193383 DOI: 10.1158/0008-5472.CAN-14-1357] [Cited by in Crossref: 34] [Cited by in F6Publishing: 24] [Article Influence: 4.9] [Reference Citation Analysis]
204 Cangelosi Q, Means SA, Ho H. A multi-scale spatial model of hepatitis-B viral dynamics. PLoS One 2017;12:e0188209. [PMID: 29216213 DOI: 10.1371/journal.pone.0188209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Hu J, Cheng J, Tang L, Hu Z, Luo Y, Li Y, Zhou T, Chang J, Guo JT. Virological Basis for the Cure of Chronic Hepatitis B. ACS Infect Dis 2019;5:659-74. [PMID: 29893548 DOI: 10.1021/acsinfecdis.8b00081] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
206 Qian H, Deng X, Huang ZW, Wei J, Ding CH, Feng RX, Zeng X, Chen YX, Ding J, Qiu L, Hu ZL, Zhang X, Wang HY, Zhang JP, Xie WF. An HNF1α-regulated feedback circuit modulates hepatic fibrogenesis via the crosstalk between hepatocytes and hepatic stellate cells. Cell Res 2015;25:930-45. [PMID: 26169608 DOI: 10.1038/cr.2015.84] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 6.3] [Reference Citation Analysis]
207 Pol JG, Lekbaby B, Redelsperger F, Klamer S, Mandouri Y, Ahodantin J, Bieche I, Lefevre M, Souque P, Charneau P, Gadessaud N, Kremsdorf D, Soussan P. Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-α-stimulated signaling pathways and limits the extent of liver inflammation. FASEB J 2015;29:1879-89. [PMID: 25630972 DOI: 10.1096/fj.14-258715] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
208 Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol. 2016;13:239-248. [PMID: 26907881 DOI: 10.1038/nrgastro.2016.7] [Cited by in Crossref: 96] [Cited by in F6Publishing: 86] [Article Influence: 19.2] [Reference Citation Analysis]
209 El-maadawy EA, Talaat RM, Ahmed MM, El-shenawy SZ. Interleukin-6 promotor gene polymorphisms and susceptibility to chronic hepatitis B virus in Egyptians. Human Immunology 2019;80:208-14. [DOI: 10.1016/j.humimm.2018.12.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
210 Liu R, Chen Y, Guo J, Li M, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Zhang H, Xie Y. The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients. BMC Infect Dis 2020;20:590. [PMID: 32778058 DOI: 10.1186/s12879-020-05320-z] [Reference Citation Analysis]
211 Jhun J, Lee S, Kim H, Her YM, Byun JK, Kim EK, Lee SK, Cho ML, Choi JY. HMGB1/RAGE induces IL-17 expression to exaggerate inflammation in peripheral blood cells of hepatitis B patients. J Transl Med 2015;13:310. [PMID: 26391982 DOI: 10.1186/s12967-015-0663-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
212 Hong MH, Chou YC, Wu YC, Tsai KN, Hu CP, Jeng KS, Chen ML, Chang C. Transforming growth factor-β1 suppresses hepatitis B virus replication by the reduction of hepatocyte nuclear factor-4α expression. PLoS One 2012;7:e30360. [PMID: 22276183 DOI: 10.1371/journal.pone.0030360] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
213 Dai X, Cai W, Wu X, Chen Y, Han F. Protocatechuic acid inhibits hepatitis B virus replication by activating ERK1/2 pathway and down-regulating HNF4α and HNF1α in vitro. Life Sciences 2017;180:68-74. [DOI: 10.1016/j.lfs.2017.05.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
214 Lucifora J, Zoulim F. The life cycle of hepatitis B virus and antiviral targets. Future Virology 2011;6:599-614. [DOI: 10.2217/fvl.11.29] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
215 Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol 2010;10:403-14. [PMID: 20498667 DOI: 10.1038/nri2780] [Cited by in Crossref: 289] [Cited by in F6Publishing: 262] [Article Influence: 26.3] [Reference Citation Analysis]
216 Wang B, Wang J, Zheng Y, Zhou S, Zheng J, Wang F, Ma X, Zeng Z. A study of TNF-alpha-238 and -308 polymorphisms with different outcomes of persistent hepatitis B virus infection in China. Pathology. 2010;42:674-680. [PMID: 21080879 DOI: 10.3109/00313025.2010.523696] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
217 Park Y, Park JY, Han KH, Kim HS. Serum cytokine levels in chronic hepatitis B patients receiving peginterferon alpha-2a therapy. Hepatobiliary Pancreat Dis Int. 2012;11:499-506. [PMID: 23060395 DOI: 10.1016/s1499-3872(12)60214-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
218 Huang LR, Gäbel YA, Graf S, Arzberger S, Kurts C, Heikenwalder M, Knolle PA, Protzer U. Transfer of HBV genomes using low doses of adenovirus vectors leads to persistent infection in immune competent mice. Gastroenterology. 2012;142:1447-50.e3. [PMID: 22426294 DOI: 10.1053/j.gastro.2012.03.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 6.2] [Reference Citation Analysis]
219 Xiang WQ, Feng WF, Ke W, Sun Z, Chen Z, Liu W. Hepatitis B virus X protein stimulates IL-6 expression in hepatocytes via a MyD88-dependent pathway. J Hepatol. 2011;54:26-33. [PMID: 20937539 DOI: 10.1016/j.jhep.2010.08.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.4] [Reference Citation Analysis]
220 Grimm D, Heeg M, Thimme R. Hepatitis B virus: from immunobiology to immunotherapy. Clin Sci (Lond). 2013;124:77-85. [PMID: 23013042 DOI: 10.1042/CS20120169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
221 Wang L, Wang K, Zou ZQ. Crosstalk between innate and adaptive immunity in hepatitis B virus infection. World J Hepatol. 2015;7:2980-2991. [PMID: 26730277 DOI: 10.4254/wjh.v7.i30.2980] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
222 Chen J, Yuan Z. Interplay between hepatitis B virus and the innate immune responses: implications for new therapeutic strategies. Virol Sin. 2014;29:17-24. [PMID: 24452540 DOI: 10.1007/s12250-014-3412-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
223 Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B Virus Immunopathology, Model Systems, and Current Therapies. Front Immunol 2017;8:436. [PMID: 28450868 DOI: 10.3389/fimmu.2017.00436] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
224 Bai L, Zhang W, Tan L, Yang H, Ge M, Zhu C, Zhang R, Cao Y, Chen J, Luo Z. Hepatitis B virus hijacks CTHRC1 to evade host immunity and maintain replication. J Mol Cell Biol. 2015;7:543-556. [PMID: 26180054 DOI: 10.1093/jmcb/mjv048] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
225 Faure-Dupuy S, Durantel D, Lucifora J. Liver macrophages: Friend or foe during hepatitis B infection? Liver Int 2018;38:1718-29. [PMID: 29772112 DOI: 10.1111/liv.13884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
226 Wang ZY, Li YQ, Guo ZW, Zhou XH, Lu MD, Xue TC, Gao B. ERK1/2-HNF4α axis is involved in epigallocatechin-3-gallate inhibition of HBV replication. Acta Pharmacol Sin 2020;41:278-85. [PMID: 31554961 DOI: 10.1038/s41401-019-0302-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
227 Fan H, Yan X, Zhang Y, Zhang X, Gao Y, Xu Y, Wang F, Meng S. Increased expression of Gp96 by HBx-induced NF-κB activation feedback enhances hepatitis B virus production. PLoS One 2013;8:e65588. [PMID: 23776506 DOI: 10.1371/journal.pone.0065588] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
228 Wang Y, Cui L, Yang G, Zhan J, Guo L, Chen Y, Fan C, Liu D, Guo D. Hepatitis B e Antigen Inhibits NF-κB Activity by Interrupting K63-Linked Ubiquitination of NEMO. J Virol 2019;93:e00667-18. [PMID: 30404796 DOI: 10.1128/JVI.00667-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
229 Tout I, Gomes M, Ainouze M, Marotel M, Pecoul T, Durantel D, Vaccarella S, Dubois B, Loustaud-ratti V, Walzer T, Alain S, Chemin I, Hasan U. Hepatitis B Virus Blocks the CRE/CREB Complex and Prevents TLR9 Transcription and Function in Human B Cells. J I 2018;201:2331-44. [DOI: 10.4049/jimmunol.1701726] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]